Global Ulcerative Colitis Market Analysis & Industry Forecast 2017-2023, With an Expected CAGR of 6.5% - ResearchAndMarkets.com

June 6, 2018

DUBLIN--(BUSINESS WIRE)--Jun 6, 2018--The “Ulcerative Colitis Market by Molecule Type - Global Opportunity Analysis and Industry Forecast, 2017-2023” report has been added to ResearchAndMarkets.com’s offering.

The global ulcerative colitis market accounted for $4,785 million in 2016 and is expected to reach $7,455 million by 2023, registering a CAGR of 6.5% from 2017 to 2023.

Ulcerative colitis (UC) is an inflammatory gastrointestinal disease that affects colon or large intestine. UC is characterized as an incurable disease with low mortality rate and is generally diagnosed in adolescence and early adulthood. As per NCBI, about 1.86 billion patients were diagnosed with UC globally in 2014, with 1.54 billion patients currently receiving treatment.

The major factors that drive the growth of the global ulcerative colitis market are increasing number of ulcerative colitis patients, new drug formulations by key players, and increasing investments by government and non-government organizations towards research in biologics. However, patent expiry and availability of alternative surgery option for UC treatment restricts the market growth.

The report segments the global ulcerative colitis market based on disease type, molecule type, and route of administration. Based on molecule type, the market is categorized as biologics and small molecules. In terms of disease type, the market is divided into mild, moderate, and severe ulcerative colitis. Based on route of administration, the market is bifurcated into oral and injectables.

Key Topics Covered:

Chapter 1. Introduction

Chapter 2. Executive Summary

Chapter 3. Market Overview

Chapter 4. Ulcerative Colitis, By Disease Type

Chapter 5. Ulcerative Colitis Market, By Molecule Type

Chapter 6. Ulcerative Colitis Market, By Route Of Administration

Chapter 7. Ulcerative Colitis Market, By Geography

Chapter 8. Company Profiles

For more information about this report visit https://www.researchandmarkets.com/research/bpsmnz/global_ulcerative?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180606005525/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Immune Disorders Drugs,Gastrointestinal Drugs



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 06/06/2018 05:21 AM/DISC: 06/06/2018 05:21 AM


Update hourly